25/10/2021

VFMCRP and Cara Therapeutics announce European Medications Agency has recognized to overview the Marketing Authorization Software for difelikefalin

ST.GALLEN, Switzerland & STAMFORD, Conn.–(Enterprise WIRE)–Regulatory Information:

Vifor Fresenius Clinical Treatment Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) now declared that the European Medicines Company (EMA) approved to evaluation the Promoting Authorization Application (MAA) for difelikefalin injection for the treatment method of pruritus related with long-term kidney illness in hemodialysis clients. The EMA will evaluation the application beneath the centralized internet marketing authorization treatment.

The EMA submitting is supported by optimistic scientific information from the two pivotal section-III trials KALM-1 and KALM-2, as very well as supportive data from an further 32 scientific scientific studies. If approved, difelikefalin would receive advertising authorization in all member states of the European Union (EU), as very well as in Iceland, Liechtenstein and Norway. EMA’s conclusion on the EU MAA is envisioned Q2-2022.

“Following the US FDA’s acceptance and priority critique for the New Drug Application for difelikefalin at the beginning of March 2021, this is one more big phase forward on our mission to enable kidney sufferers around the earth direct far better, more healthy life,” commented Stefan Schulze, CEO of Vifor Pharma Team. “Together with our associate Cara Therapeutics, we keep on being focused on creating this modern therapy readily available in Europe, if authorised, for clients with chronic kidney illness-associated pruritus, a problem that has been historically underdiagnosed and undertreated.”

“The acceptance of the EU regulatory software for difelikefalin marks a further main milestone in direction of our intention of bringing this initially-in-course therapeutic to the sizeable amount of hemodialysis patients around the world with chronic intractable pruritus,” explained Derek Chalmers, Ph.D., D.Sc., President and Chief Government Officer of Cara Therapeutics. “We glance forward to doing the job closely with our associate, Vifor Pharma, by way of the EMA overview course of action and in preparation for commercial launch throughout European territories, if authorized.”

About Vifor Pharma Team

Vifor Pharma Team is a world-wide prescription drugs organization. It aims to turn into the worldwide chief in iron deficiency, nephrology and cardio-renal therapies. The company is a spouse of decision for prescribed drugs and progressive affected individual-focused solutions. Vifor Pharma Group strives to assistance patients all around the entire world with extreme and serious ailments direct far better, much healthier lives. The company develops, manufactures and markets pharmaceutical merchandise for precision affected individual treatment. Vifor Pharma Team holds a main posture in all its main organization activities and consists of the pursuing firms: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint business with Fresenius Clinical Care). Vifor Pharma Group is headquartered in Switzerland, and shown on the Swiss Inventory Trade (6 Swiss Exchange, VIFN, ISIN: CH0364749348).

For far more details, be sure to stop by viforpharma.com.

About Cara Therapeutics

Cara Therapeutics is a medical-phase biopharmaceutical business centered on creating and commercializing new chemical entities built to alleviate pruritus by selectively focusing on peripheral kappa opioid receptors, or KORs. Cara is producing a novel and proprietary class of product or service candidates, led by KORSUVA™ (CR845/difelikefalin), a to start with-in-course KOR agonist that targets the body’s peripheral nervous procedure, as nicely as selected immune cells. In two Phase 3 trials, KORSUVA injection has shown statistically considerable reductions in itch intensity and concomitant improvement in quality of lifestyle actions in hemodialysis patients with moderate-to-critical continual kidney condition-involved pruritus (CKD-aP). Oral KORSUVA™ has properly done a Phase 2 trial for the therapy of pruritus in people with CKD and is at present in Section 2 trials in atopic dermatitis, key biliary cholangitis and notalgia paresthetica sufferers with average-to-critical pruritus.

About Continual Kidney Disorder-related Pruritus (CKD-aP)

CKD-aP is an intractable systemic itch ailment that occurs with substantial frequency and intensity in patients with long-term kidney sickness going through dialysis. Pruritus has also been reported in sufferers with phase III-V CKD who are not on dialysis. The majority of dialysis sufferers (about 60 to 70%) report pruritus, with 30 to 40% reporting average or serious pruritus.1,2,3 Modern info from the ITCH Countrywide Registry Research confirmed that amongst those with pruritus, roughly 59% experienced symptoms day-to-day or almost each day for a lot more than a calendar year. Specified its association with CKD/ESRD, most stricken sufferers will continue on to have signs and symptoms for months or many years, with at the moment used antipruritic treatment options, such as antihistamines and corticosteroids, unable to offer regular, ample reduction. Average-to-severe long-term pruritus has frequently been proven to straight lessen high-quality of everyday living, add to indicators that impair good quality of lifestyle (these kinds of as poor sleep high-quality), and is related with melancholy.4 CKD-aP is also an independent predictor of mortality and the danger for hospitalization among hemodialysis patients.

Ahead-wanting Statements

Statements contained in this push release concerning issues that are not historical info are “forward-on the lookout statements” within the meaning of the Non-public Securities Litigation Reform Act of 1995. Examples of these forward-seeking statements incorporate statements relating to the likely regulatory acceptance of difelikefalin resolution for injection and the potential timeline for EMA evaluation and acceptance of the MAA and the possible of difelikefalin alternative for injection to be a therapeutic selection for CKD-aP in dialysis dependent patients. For the reason that these kinds of statements are topic to risks and uncertainties, actual results may differ materially from these expressed or implied by these types of forward-wanting statements. Pitfalls are explained extra thoroughly in Cara’s filings with the Securities and Trade Commission, together with the “Danger Variables” part of Cara’s Annual Report on Form 10-K for the calendar year ended 31 December 2020 and its other files subsequently filed with or furnished to the Securities and Exchange Fee. All ahead-seeking statements contained in this press launch discuss only as of the day on which they have been built. Apart from to the extent needed by regulation, Cara undertakes no obligation to update these kinds of statements to replicate occasions that come about or conditions that exist immediately after the date on which they have been made.

References:

1 Pisoni RL, et al. Pruritus in haemodialysis individuals: worldwide outcomes from the Dialysis Results and Practice Designs Review. Nephrol Dial Transplant. 2006 21:3495-3505.

2 Ramakrishnan K, et al. Clinical attributes and outcomes of finish-phase renal disease patients with self-described pruritus indications. Worldwide Journal of Nephrology and Renovascular Disorder. 2014 7: 1-12.

3 Sukul et al. Self-reported Pruritus and Scientific, Dialysis-Similar, and Client-Claimed Results in Hemodialysis Patients. Kidney Med. 2020 Nov 213(1):42-53.

4 Mathur VS, et al. A longitudinal analyze of Uremic Pruritus in hemodialysis clients. Clin J Am Soc Nephrol. 2010 5(8):1410-1419.